Rubius Therapeutics Inc RUBY:NASDAQ

Last Price$10.60NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/16/19

Today's Change+0.61(6.11%)
Bid (Size)$10.61 (28)
Ask (Size)$10.63 (13)
Day Low / High$10.05 - 10.87
Volume299.0 K
 

View Biotechnology IndustryPeer Comparison as of 08/16/2019

 

Rubius Therapeutics Inc ( NASDAQ )

Price: $10.60
Change: +0.61 (6.11%)
Volume: 299.0 K
4:00PM ET 8/16/2019
 
 

Intellia Therapeutics Inc ( NASDAQ )

Price: $17.41
Change: +0.51 (3.02%)
Volume: 859.1 K
3:59PM ET 8/16/2019
 
 

Adverum Biotechnologies Inc ( NASDAQ )

Price: $13.41
Change: +0.01 (0.07%)
Volume: 1.5 M
3:59PM ET 8/16/2019
 
 

ZIOPHARM Oncology Inc ( NASDAQ )

Price: $5.06
Change: 0.00 (0.00%)
Volume: 1.3 M
3:59PM ET 8/16/2019
 
 

Vanda Pharmaceuticals Inc ( NASDAQ )

Price: $15.19
Change: +0.28 (1.88%)
Volume: 724.3 K
4:00PM ET 8/16/2019
 

Read more news Recent News

Rubius Therapeutics Posts Wider-Than-Expected Q2 Loss
9:35AM ET 8/13/2019 MT Newswires

Rubius Therapeutics (RUBY), a clinical-stage biopharmaceutical company, reported pre-market Tuesday a wider-than-estimated loss for its most recent...

Rubius Therapeutics Files $450 Mln Mixed Shelf Registration
7:48AM ET 8/02/2019 MT Newswires

Rubius Therapeutics (RUBY) has filed a $450 million mixed shelf registration with the US Securities and Exchange Commission. The company may offer common...

Analyst Actions: HC Wainwright Initiates Coverage on Rubius Therapeutics at Buy, Price Target $40
8:36AM ET 6/26/2019 MT Newswires

Rubius Therapeutics (RUBY) has an average rating among analysts of buy, with an average price target of $35 Price: 14.80, Change: +0.20, Percent Change:...

Rubius Therapeutics Wins Three Patents on Rare Diseases, Oncology Programs
8:29AM ET 6/05/2019 MT Newswires

Rubius Therapeutics Inc. (RUBY), a developer of off-the-shelf cellular medicines, unveiled early Wednesday the issuance of three patents from the US Patent...

Company Profile

Business DescriptionRubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan and is headquartered in Cambridge, MA. View company web site for more details
Address399 Binney Street
Cambridge, Massachusetts 02139
Phone+1.617.679.9600
Number of Employees142
Recent SEC Filing08/13/20198-K
Chief Executive Officer & DirectorPablo J. Cagnoni
Senior Vice President-Finance & OperationsJoanne M. Protano
Chief Financial OfficerAndrew M. Oh
Vice President-Research & DevelopmentThomas Wickham

Company Highlights

Price Open$10.11
Previous Close$9.99
52 Week Range$9.96 - 26.90
Market Capitalization$844.3 M
Shares Outstanding79.7 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/12/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$4.39
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-34.25%

Analyst Ratings as of 08/09/2019

Buy
6
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset